Streetbeat News

NVZMY

Novonesis AS

https://www.novozymes.com/

CEO

Ester Baiget

Open

56.77

Mkt cap

27B

Volume

518

High

56.96

P/E Ratio

57.59

52-wk high

72.50

Low

56.44

Div yield

0.03

52-wk low

49.99

Novonesis, a company formed from Chr. Hansen and Novozymes, is showing promising growth with a 9% increase in organic sales for 9M24. Despite a decrease in P/E ratio from 40x to 33x, the company remains overvalued. Growth is driven by new products and emerging markets, but risks include reliance on GDP-like growth in core markets and volatility in energy/bioenergy sectors.

Portfolio Pulse from

November 08, 2024 | 2:15 pm

Novozymes (OTC:NVZMY) reported Q4 earnings with an EPS of $0.36, missing estimates by 18.18% against an expected $0.44. Revenue increased by $58.13 million from the previous year. In contrast, the company had previously beaten EPS estimates in Q3 2023, leading to a 2.66% share price increase the following day.

Portfolio Pulse from Benzinga Insights

February 01, 2024 | 2:30 pm

Novozymes (OTC:NVZMY) is set to release its quarterly earnings report on October 26, 2023. Analysts estimate an EPS of $0.42. The company's past performance shows a mixed trend of beating and missing EPS estimates, with the share price reacting accordingly. The stock is currently trading at $39.75, down 25.56% over the last 52-week period.

Portfolio Pulse from Benzinga Insights

October 25, 2023 | 8:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.